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ABSTRACT 
Background & Aims: One important hypothesis in primary sclerosing cholangitis (PSC) 
pathophysiology suggests that bacterial products from an inflamed leaky gut leads to biliary 
inflammation. We aimed to investigate whether circulating markers of bacterial translocation 
were associated with survival in a Norwegian PSC cohort.  
Methods: Serum levels of zonulin, intestinal fatty acid binding protein, soluble CD14 
(sCD14), lipopolysaccharide (LPS) and LPS-binding protein (LBP) were measured in 166 
PSC patients and 100 healthy controls (HC).  
Results: LBP and sCD14 were elevated in PSC compared with HC (median 13662 vs 12339 
ng/mL, P=0.010 and 1657 vs. 1196 ng/mL, P<0.001, respectively). High sCD14 and LBP 
(values>optimal cut-off using receiver operating characteristics) were associated with reduced 
liver transplantation-free survival (P<0.001 and P=0.005, respectively). The concentration of 
sCD14 was higher in patients with hepatobiliary cancer compared to other PSC patients and 
HC. Zonulin was lower in PSC than controls, but when excluding PSC patients with increased 
prothrombin time zonulin concentrations were similar in PSC and HC. Concomitant 
inflammatory bowel disease did not influence the results, while IBD patients without PSC 
(n=40) had lower concentration of sCD14. In multivariable Cox regression, high sCD14 and 
high LBP were associated with transplantation-free survival, independent from Mayo risk 
score (HR 2.26 (95%CI 1.15-4.43), P=0.018 and HR 2.00 (95% CI 1.17-3.43), P=0.011, 
respectively).  
Conclusions: PSC patients show increased levels of circulating markers of bacterial 
translocation. High levels are associated with poor prognosis measured by transplantation-free 
survival, indicating that ongoing gut leakage could have clinical impact in PSC. 
Electronic word count: 250 words 
Keywords: primary sclerosing cholangitis; gut leakage markers; sCD14; LBP; LPS; zonulin. 
 4 
 
KEY POINTS BOX 
 
• Key point 1. The circulating levels of soluble CD14 and 
lipopolysaccharide-binding protein were higher in patients with primary 
sclerosing cholangitis compared with healthy controls. 
• Key point 2. High levels of the same markers were associated with 
shorter liver transplantation-free survival in the PSC patients, 
independent from Mayo risk score.  
• Key point 3. The concentration of sCD14 was particularly high in 
patients with hepatobiliary cancer 
• Key point 4. Overall, the results suggest that impaired gut barrier 
function may be relevant for disease severity and progression in primary 
sclerosing cholangitis.  
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INTRODUCTION 
Primary sclerosing cholangitis (PSC) is a chronic inflammatory liver disease affecting intra- 
and extrahepatic bile ducts, eventually progressing to end-stage liver disease.1 There is 
currently no medical treatment available. In a recent large international cohort study, median 
liver transplantation-free survival was 14.5 years,2 while it was 21.3 years in an Dutch 
population-based study.3 A feared complication is hepatobiliary malignancy, occurring in 
10% of the patients.2 Approximately 70% of the PSC patients are diagnosed with concomitant 
inflammatory bowel disease (IBD), predominantly affecting the colon.1  
The close relationship with IBD is the basis of several important hypotheses of PSC 
pathogenesis. Recent studies have identified an altered gut microbiota in PSC patients, both in 
stool and the mucosa.4 It has previously been hypothesized that leakage of bacterial products 
across an impaired mucosal barrier in the gut could contribute to the disease. The liver is 
continuously exposed to a large variety of substances, including nutrients, gut bacteria and 
bacterial products originating from the gut via the portal circulation. Disruption of the 
mucosal gut barrier, during e.g. alcohol consumption,5 inflammation or infection,6 can lead to 
increased hepatic exposure to a range of bacterial byproducts and metabolites which in turn 
can activate the immune system and trigger inflammation both systemically and in the liver.7 
Changes in the gut microbiota have also been associated with increased gut permeability,8,9 
As a proof-of-principle, induction of small intestinal bacterial overgrowth in a rat model has 
been shown to increase translocation of bacterial products and lead to pathological changes 
similar to those seen in human PSC.10 In human PSC, however, intestinal permeability has 
only been measured in one small study, and no alterations were observed.11  
The classical marker of bacterial translocation is lipopolysaccharide (LPS), which are 
glycolipids derived from the outer membrane of gram negative bacteria functioning as 
pathogen associated molecular patterns, eliciting strong immune responses.12 LPS-binding 
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protein (LBP) is an acute phase protein that binds to and correlates with LPS,13 and facilitates 
the association between LPS and soluble CD14 (sCD14). Furthermore, sCD14 mediates the 
interaction of LPS with cells, thereby signaling the presence of gram-negative bacteria.14 The 
concentration of sCD14 thus represents a host response to translocation measure, mainly 
related to monocyte activation. Zonulin is the only known physiological regulator of 
intercellular tight junctions and has been shown to correlate with intestinal permeability and 
could thus be used as a measurement of impaired gut barrier function.15 Patients with 
inflammatory diseases like celiac disease and type 1 diabetes also show increased serum 
levels of zonulin compared to controls.15 Finally, intestinal fatty acid binding protein (IFABP) 
is a biomarker for intestinal epithelial cell damage both in vivo and in vitro.16  
Only limited data and non-conclusive studies are available about some of these markers in 
PSC.17,18 Based on the observations described above, we hypothesized that circulating 
markers of gut barrier function are elevated in PSC compared with controls and that high 




PATIENTS AND METHODS 
Patient population and data collection 
Diagnosis of PSC was based on typical findings on magnetic resonance cholangiography or 
endoscopic retrograde cholangiography (ERCP) according to established criteria.1 Patients 
were recruited at admission to Oslo University Hospital Rikshospitalet in the period 2008 to 
2015. Serum and plasma were collected according to a standardized protocol and stored at -80 
degrees until analysis. The time of the first diagnostic cholangiogram defined the time of 
diagnosis. Duration of disease was defined as the time from diagnosis to serum sampling.  
Some patients had serum sampled before final diagnosis (i.e. negative disease duration). 
Clinical and demographic information was acquired from patient records and research 
databases regarding clinical and laboratory data, including ascites, encephalopathy, variceal 
bleeding, type of inflammatory bowel disease, colorectal or hepatobiliary malignancy, and 
medication at the time of serum extraction. Inflammatory bowel disease was diagnosed based 
on endoscopy and histological findings, according to accepted criteria.19 Healthy controls 
(n=100) were included from the Norwegian Bone Marrow Donor Registry, as used in 
previous studies.20 IBD patients with a final diagnosis of ulcerative colitis but without PSC 
(n=40), were included from the Inflammatory Bowel Disease in South-Eastern Norway 
(IBSEN) population-based inception cohort. Serum was sampled at the 10-year follow-up.20 
Written informed consent was obtained from each study participant. The Regional Committee 
for Medical and Health Research Ethics of South-Eastern Norway approved the study 
(Reference: 2015/2140/REK). The study was carried out in accordance with the Declaration 
of Helsinki. 
Analysis of markers of bacterial translocation and clinical biochemistry 
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Child-Pugh score, Model for End-Stage Liver Disease (MELD) score and revised Mayo risk 
score were calculated according to established algorithms.21-23 Since only data on 
presence/absence (and not severity) of ascites/ hepatic encephalopathy were available, only 
one additional point was given for ascites or hepatic encephalopathy when calculating the 
Child-Pugh score. Serum concentrations of IFABP, zonulin, LBP and sCD14 were analyzed 
with enzyme-linked immunosorbent assay (ELISA) kits: IFABP and LBP (Hycult biotech, 
Uden, The Netherlands, coefficient of variation (CV) 8.2% and 7.6%, respectively), Zonulin 
(Immune diagnostic, Bensheim, Germany, CV 12.5%) and sCD14 (R&D Systems, Abington, 
Oxon, UK, CV 8.9%). LPS analysis (in plasma) was established after testing several methods. 
A pilot study of 40 PSC samples using the commonly applied limulus amebocyte lysate 
colorimetric assay (Lonza, Walkersville, MD, USA) revealed a strong correlation between 
LPS and bilirubin concentrations (rho=0.75, P < 0.001), suggesting that bilirubin interferes 
with the yellow read-out of the test. LPS analyses were therefore performed using the 
Pyrochrome Diazo kit (Cape Cod, East Falmouth, MA, USA, CV 15.0%) according to the 
manufacturer's instructions, and no correlation with bilirubin concentration was found (rho = 
0.045, P=0.58). Standard biochemical analyses were performed as part of clinical routine, 
including liver function tests and international normalized ratio (INR). 
Statistical analyses 
Data are presented as median (range) unless stated otherwise. The Mann–Whitney U test was 
applied for continuous variables. Correlation between levels of gut leakage markers zonulin, 
IFABP, sCD14, LBP and LPS were performed by the Spearman’s rank correlation test (rho). 
Kaplan-Meier plots and log-rank tests were used for survival analyses. The biomarkers of 
interest were categorized as high and low levels by the median (2 ntiles-option in SPSS). 
Receiver operating characteristics (ROC) curve analyses were performed to define area under 
the curve (AUC), sensitivity and specificity, as well as the optimal cut-offs using Youden’s 
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index.  When analyzing subgroups, the samples were re-categorized in each stratum. Clinical 
features and laboratory data from the time of sampling was compared with mortality or liver 
transplantation with Cox proportional hazards analysis. Statistical analyses were performed 
using SPSS (version 24; SPSS, Inc., Chicago, IL) and MedCalc (MedCalc Software, Ostend, 
Belgium). P-values <0.05 were considered statistically significant. 
RESULTS  
Population characteristics 
In total 166 PSC patients (80% male, 73% with IBD) and 100 healthy controls (59% male) 
were included, with a median age of 41.0 (16.3–72.4) years in the PSC patient group and 39.9 
(28.1–56.1) in the control group (Table 1). During a median follow-up time of 3.9 (0.0–8.3) 
years 74 (45%) of the PSC patients reached an end point; 19 patients died and 55 patients 
underwent liver transplantation.  
Increased sCD14 and LBP concentrations in PSC patients compared with controls 
The concentration of sCD14 was higher in the PSC patients compared to controls, median 
1657 (885-4095) and 1196 (835–1776) ng/ml, P<0.001, respectively (Figure 1A). LBP was 
also higher in PSC patients than controls (13662 (4856–34311) vs. 12339 (4674–43400) 
ng/ml, (P=0.010), Figure 1B), while zonulin was lower in the patients (32 (6-58) vs. 34 (14–
55) ng/ml, (P=0.008), Figure 1C). IFABP and LPS were similar in PSC patients and controls 
(P=0.20, Figure 1D and P=0.84, Figure 1E, respectively). There was a modest but significant 
correlation between sCD14 and LBP in PSC patients (rho=0.22, P=0.005, Figure 1F), but not 
in healthy controls (rho=-0.07, P=0.46). Similarly, sCD14 and LPS were correlated in PSC 
patients (rho=0.23, P=0.003), but not in healthy controls (rho=0.03, P=0.78). There were no 
significant differences in levels of gut leakage markers between PSC patients with and 
without IBD, but IBD without PSC had lower levels of sCD14 than PSC patients (Figure 2A 
and B). PSC patients using ursodeoxycholic acid (UDCA) showed higher levels of sCD14 
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compared to other PSC patients (1848 (973-3264) vs 1540 (885-4095), P=0.005). Patients on 
prednisolon or 5-aminosalicylic acid treatment showed similar levels of sCD14 as other 
patients (data not shown). 
High sCD14 and LBP predict reduced liver transplantation-free outcome 
PSC patients who reached an end point (death or liver transplantation) during follow up 
showed higher concentrations of sCD14 compared to transplantation-free survivors (2047 
(895–4095) vs. 1496 (885–2713) ng/ml, P<0.001). Similarly, LBP was also increased in 
patients with end point during follow up compared to transplantation-free survivors (14302 
(4856–34311) vs. 13076 (5013–29557) ng/ml, P=0.046). There were no significant 
differences for LPS, zonulin or IFABP (data not shown).  
In order to evaluate the predictive value of sCD14 and LBP, the patients were stratified into 
high and low concentration by the median and analyzed by Kaplan-Meier plots and log rank 
tests. Patients with high sCD14 or high LBP concentrations showed reduced liver 
transplantation-free survival compared with the low concentrations groups (P<0.001 and 
P=0.043, respectively). There were no significant effects on survival for LPS, zonulin or 
IFABP (data not shown). ROC tests were subsequently performed to define the optimal cut-
offs in the complete PSC population. The AUC of sCD14 to differentiate patients with and 
without end-point was 0.76 with an optimal cut-off of >1638 ng/ml, associated with a 
sensitivity of 74% and specificity of 70% (Figure 3A). LBP yielded an AUC of 0.59, with the 
optimal cut-off >13942 ng/ml (sensitivity of 55% and specificity of 64%, Figure 3B). Using 
the optimal cut-offs, sCD14>1638 ng/ml was associated with reduced liver transplantation-
free survival, mean 3.5 years (CI 2.7-4.2) vs. 6.8 (6.2-7.4), P<0.001, while LBP>13942 ng/ml 
was associated with a mean survival of 4.3 years (3.4-5.1) vs. 5.8 (5.1-6.5), P=0.005 (Figure 
3C and 3D).  
Concentration of sCD14 was higher in the groups with hepatobiliary cancer 
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Of the 166 PSC patients, 25 had a diagnosis of hepatobiliary malignancy at baseline, or were 
diagnosed during follow-up (22 of them had cholangiocarcinoma (CC) and 3 had gallbladder 
cancer (GBC)). The concentration of sCD14 was higher in the cancer groups than in PSC 
patients without cancer and healthy controls (Figure 4A), while there were no significant 
differences for the other markers. When stratifying according to the occurrence of cancer or 
not, there was still a strong association between high sCD14 and reduced liver 
transplantation-free survival in the group without cancer (Figure 4B).  
Zonulin concentration is confounded by liver synthesis function  
Zonulin (encoded by the Haptoglobin gene) is primarily synthesized in the liver. Zonulin 
concentration was significantly lower (P=0.001) in PSC patients with reduced synthesis 
function, as defined by increased prothrombin time (INR>1.2), which was available for 134 
PSC patients. When only including patients with normal liver function (n=115), patients with 
PSC no longer had reduced zonulin levels compared with healthy controls (Figure 5A). There 
were no significant differences in the other markers between patients with high and low INR. 
High levels of sCD14 were associated with reduced liver transplantation-free survival 
regardless of high or low INR (Figure 5B and C). When using other measures of advanced 
chronic liver disease, Child-Pugh score and MELD score, sCD14 was significantly higher in 
patients with more advanced disease (Child-Pugh B/C vs. A or MELD >=10 vs <10), 2331 
(895–4095) vs 1535 (885–2956) and 2420 (895–4095) vs 1574 (885–3264), respectively 
(both P<0.0001). However, high sCD14 (>1638 ng/ml) was not significantly associated with 
liver transplantation-free survival in the Child-Pugh B/C and MELD>10 groups (Data for 
Child-Pugh score shown in Figure 5D and 5E), suggesting that the strongest predictive power 
is in less advanced disease. 
Relationship between cholangitis, cholestasis and gut leakage markers 
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In PSC, the presence of acute cholangitis may nonspecifically confound the investigated 
markers. C-reactive protein (CRP) correlated with sCD14 (rho=0.47, P<0.001), LPS 
(rho=0.22, P=0.007) and leukocytes (rho=0.20, P=0.015). Considering an arbitrary cut-off of 
CRP>10 mg/L, n=40 (26%) of the patients had elevated and n=112 (74%) normal CRP (n=8 
missing values). Elevated CRP was associated with reduced liver transplantation-free survival 
(log rank P<0.001), however, elevated sCD14 was still associated with decreased survival 
when patients with high CRP were excluded (Figure 6A).  
A moderate to strong correlation was observed between cholestasis markers and sCD14, 
demonstrated for alkaline phosphatase (rho 0.58, P <0.0001) and bilirubin (rho 0.63, 
P<0.0001), while only a weak correlation was seen between LBP and bilirubin (rho 0.17, 
P<0.038), Figure 6B-D. 
No relationship with genetic variation in the CD14 gene 
Other possible confounders are genetic determinants of sCD14 expression. In a previous 
study in PSC patients, genetic variation in the rs2569190 single-nucleotide polymorphism in 
the CD14 gene correlated with sCD14 concentration.18 However, when using genotype data 
of rs2569190 available from 72 of the included PSC patients from a previous study,24 there 
was no relationship between rs2569190 genotype and circulating sCD14 concentration in the 
present cohort, irrespective of genetic model (genotype or dominant/recessive, data not 
shown).  
Independent effects of sCD14 and LBP in multivariable Cox regression 
Cox regression was performed to assess the relationship between sCD14, LBP and established 
risk factors in PSC. We found both elevated sCD14 and LBP to be associated with reduced 
liver transplantation-free survival in PSC, independent of Mayo risk score (which entail age, 
albumin, bilirubin and AST), the presence of reduced synthesis function (elevated INR) or a 
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cancer phenotype (occurrence of hepatobiliary cancer), while elevated CRP was not 
significantly associated with survival in multivariable models (Table 2). 
DISCUSSION 
In this cross-sectional study of circulating markers related to bacterial translocation, intestinal 
permeability and monocyte activation, sCD14 and LBP were elevated in PSC patients 
compared with controls. High levels of sCD14 and LBP were associated with reduced liver 
transplantation-free survival, suggesting that bacterial translocation may be relevant for 
disease progression in PSC. Of note, elevated sCD14 was associated with reduced survival 
even when excluding individuals that were later diagnosed with hepatobiliary cancer, which 
was associated with the highest sCD14 levels.  
Serum concentrations of both sCD14 and LBP were clearly elevated in PSC patients. To our 
knowledge, there are no previous reports comparing circulating sCD14 and LBP in PSC or 
other cholestatic diseases with healthy controls. In non-alcoholic fatty liver disease, elevated 
levels of sCD14 were observed in a study of 113 patients and 21 matched healthy controls, 
positively correlating with both liver inflammation grade and hepatic sCD14 expression.25 
Elevated sCD14 has also been reported in systemic inflammatory diseases like arthritis 26 and 
atopic dermatitis.27 The correlations between sCD14 and LBP, and sCD14 and LPS, suggest 
that translocation of gut microbial products may in part influence sCD14 concentrations, 
despite no increase of LPS observed in the systemic circulation. Importantly, sCD14 has been 
found to be elevated in bile in PSC compared with control subjects undergoing ERCP,20 
indicating that a biliary source of sCD14 is possible. LPS has been reported to accumulate in 
the biliary epithelium of PSC patients, which also shows hyper-responsiveness to LPS 
stimulation.28-30 One could therefore speculate that there is an increase in LPS in portal blood, 
which is no longer detectable after first passage of the liver. 
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High sCD14 and LBP were associated with liver transplantation-free survival independent of 
Mayo risk score. This is in line with a study of 136 Japanese patients with primary biliary 
cholangitis (PBC) followed for 8.8 years, where elevated sCD14 at baseline was significantly 
associated with both liver decompensation and liver-related death or liver transplantation.31 In 
contrast to our findings, a recent German study in PSC showed increasing sCD14 associated 
with reduced risk of liver transplantation or death.18 The sCD14 concentrations in that study 
correlated with a common genetic variant of CD14; CD14 -260C>T (rs2569190). A similar 
correlation was not reproduced in the present study, suggesting that there were major 
differences between the cohorts. The positive correlations between sCD14, LBP and LPS 
suggest that sCD14 concentrations in our patient cohort, at least in part, are driven by pro-
inflammatory stimuli and not host genes. These results are also coherent with the association 
between LBP and reduced liver transplantation-free survival. The German study excluded 
patients with advanced disease or acquiring cancer, contributing to the differences between 
the cohorts.18 Still, the contradictory observations regarding sCD14 and liver transplantation-
free survival are difficult to fully explain and warrant further studies. 
A critical question when evaluating markers of bacterial translocation in PSC is the disease 
stage, since cirrhosis per se influences the gut barrier,32 as well as confounding factors like 
acute cholangitis and cholestasis. Structural and functional alterations of the gut mucosa that 
lead to increased intestinal permeability have been described in liver cirrhosis 33 and increased 
intestinal permeability has been linked to the progression of liver disease and the 
complications of cirrhosis.34 In the present study, neither sCD14 nor LBP were affected by the 
presence of reduced liver synthesis function, as measured by INR. However, reduced liver 
synthesis function may explain the reduced concentration of zonulin, which is only 
synthesized in the liver. In contrast, sCD14 was highly elevated and lost predictive power in 
patients with advanced chronic liver disease as evaluated by Child-Pugh score and MELD, 
suggesting that the effects of cirrhosis and portal hypertension outweigh any early gut barrier 
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dysfunction. We are uncertain why the use of UDCA was associated with higher sCD14 
concentration. UDCA is of limited use in Norway and one possibility is that it is given mainly 
to symptomatic patients, who could have higher disease activity.  
LBP and sCD14 both correlated with CRP, which is in line with elevated levels observed 
during acute cholangitis.35 Elevated sCD14 and LBP concentrations have also been observed 
in patients with distal obstructive jaundice.36 The correlations observed in particular between 
sCD14 and alkaline phosphatase as well as bilirubin could therefore suggest that cholestasis 
per se increases sCD14, although an alternative cause could be the mechanisms driving 
cholestasis. The elevated sCD14 levels in PSC, irrespective of concomitant IBD, compared 
with IBD patients without PSC may also point to the liver as an important driving force. 
Given the similar concentrations of LPS, IFABP and zonulin (in the group with normal 
synthesis) in the patients compared with controls, one should therefore be careful before 
concluding that increased bacterial translocation is the only or major explanatory factor for 
the present observations. This is in line with the lack of changes in small-bowel intestinal 
permeability observed in the only permeability study so far published in PSC,11 although one 
could argue its relevance given that PSC patients most often experience colonic IBD. 
However, sCD14 and LBP were similar in PSC patients with and without a diagnosis of IBD, 
suggesting either that IBD is less relevant, or that an undiagnosed subclinical inflammatory 
intestinal process is ongoing also in PSC patients without IBD. Of note, the by far highest 
concentrations of sCD14 were observed in patients with hepatobiliary cancer. It could be 
speculated that this is partly related to activated tumor associated macrophages, and serves as 
rationale for further studies related to sCD14 or other macrophage-related markers in the 
pathogenesis or as clinical biomarkers in cholangiocarcinoma.  
Some limitations should be discussed. The cohort is fairly large, but the results are not 
independently validated. Missing data for some confounders reduced the number of included 
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patients in the multivariable model. All patients have been included at a tertiary referral 
center, suggesting that the cohort may represent PSC phenotypes at the severe part of the 
disease spectrum. All assays were tested and found reproducible in our lab, but may have 
limitations; e.g. IFABP may be more useful in acute damage and LPS has a short half-life and 
variability in detection rates.32 The extensive work to identify an assay not influenced by 
bilirubin is however a strength of the present study. 
In conclusion, sCD14 and LBP were elevated in PSC patients compared with controls. These 
markers were moderately correlated, and high concentrations were associated with reduced 
liver transplantation-free survival independent from Mayo risk score, the occurrence of 
hepatobiliary cancer and reduced synthesis function. This opens the possibility that bacterial 
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Table 1. Patient characteristics. 
 All PSC patients Liver Tx-free survivors Liver Tx/death P 
 n = 166 n = 92 n = 74  
Males, n (%) 132 (80) 74 (80) 58 (78) 0.847 
Age, years, median (range) 41.0 (16.3-72.4) 36.3 (16.3-67.3) 48.0 (21.2-72.4) <0.001 
Age at diagnosis, years, median (range) 34.7 (13.2-71.5) 31.1 (13.8-65.8) 40.4 (13.2-71.5) <0.001 
PSC duration, years, median (range)* 1.6 (-0.74-32.1) 0.7 (-0.7-32.1) 2.7 (-0.6-26.5) 0.205 
IBD ever, n (%) 121 (73) 72 (78.3) 49 (66.2) 0.051 
Follow-up, years, median (range)  3.9 (0.01-8.3) 6.4 (1.8-8.3) 0.6 (0.01-7.3) <0.001 
Liver transplant, n (%) 55 (33) 0 55 (74)  
Death as endpoint, n (%) 19 (11) 0 19 (26)  
Mayo risk score, median (range) 0.06 (-3.0-4.13) -0.25 (-2.99-3.20) 0.98 (-1.70-4.13) <0.001 
Ursodeoxycholic acid, n (%) 52 (31) 23 (25) 29 (39) 0.061 
Prednisolon, n (%) 39 (23) 16 (17) 23 (31) 0.042 
5-Aminosalicylic acid, n (%) 54 (33) 27 (29) 27 (36) 0.313 
Laboratory data     
ALP, U/L, median (range) 225 (51-1459) 198 (51-869) 283 (78-1459) <0.001 
ALT, U/L, median (range) 90 (14-1008) 79 (14-885) 98 (24-1008) 0.420 
AST, U/L, median (range) 75 (16-1683) 59 (16-1219) 99 (20-1683) <0.001 
Albumin g/L, median (range) 41 (23-51) 42 (31-51) 37 (23-48) <0.001 
Total bilirubin g/100 mL , median (range) 23 (3-591) 14 (3-167) 42 (5-591) <0.001 
Creatinine µmol/L, median (range) 65 (18-137) 68 (28-119) 62 (18-137) 0.069 
Platelets 109, median (range) 283 (22-903) 293 (70-903) 244 (22-819) 0.030 
Other information     
Gall bladder cancer, n (%) 3 (2) 0 3 (4) 0.090 
Cholangiocarcinoma, n (%) 22 (13) 1 (1) 21 (28) <0.001 
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PSC, primary sclerosing cholangitis, Tx, transplantation; IBD, inflammatory bowel disease; 
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase. 
*A few patients have “negative” disease duration since diagnosis of PSC is set to the first 
definitive diagnostic cholangiogram. 
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Table 2. Cox regression analysis of PSC patients. 
 Univariate analysis Multivariate analysis# 
 P HR 95 % CI  N P HR 95 % CI  N 
Gender 0.708 1.11 0.64-1.94 166     
IBD 0.034 1.69 1.04-2.74 164 0.075 0.61 0.35-1.05 131 
Mayo risk score <0.001 1.85 1.56-2.20 154 0.008 1.43 1.10-1.86 131 
IFABP (high*) 0.926 1.02 0.65-1.61 166     
Zonulin (high*) 0.973 0.99 0.63-1.57 166     
sCD14 (high*) <0.001 4.63 2.71-7.91 165 0.018 2.26 1.15-4.43 131 
LBP (high*) 0.006 1.92 1.21-3.04 166 0.011 2.00 1.17-3.43 131 
LPS (high*) 0.212 1.34 0.84-2.13 166     
INR > 1.2 <0.001 4.09 2.28-7.30 134 0.007 2.54 1.29-5.01 131 
CRP > 10 <0.001 3.24 2.01-5.23 154 0.38 0.74 0.38-1.45 131 
Hepatobiliary 
cancer (yes) 
<0.001 5.79 3.46-9.67 165 0.001 2.86 1.50-5.47 131 
 
#All the significant variables (P < 0.05) from a univariate cox regression analysis were 
included in a multivariate model. *For IFABP, zonulin and LPS, median was used as cut-off, 
while the cut-offs for sCD14 were >1638 ng/ml and LBP > 13942 ng/ml, which were the 
optimal cut-offs from area under the curve analysis. HR, hazard ratio; PSC, primary 
sclerosing cholangitis; IBD, inflammatory bowel disease; IFABP, intestinal fatty acid binding 
protein; sCD14, soluble CD14; LBP, lipopolysaccharide binding protein; LPS, 




Fig. 1. Levels of gut leakage markers in primary sclerosing cholangitis (PSC) patients vs. 
healthy controls. PSC patients (n = 166) show a significant increase in (A) soluble CD14 
(sCD14), (B) lipopolysaccharide-binding protein (LBP) and (C) decrease in zonulin 
compared to healthy controls (n = 100), while levels of (D) intestinal fatty acid binding 
protein (IFABP) and (E) lipopolysaccharide (LPS) levels were similar. (F) Scatterplot of 
sCD14 and LBP levels in PSC patients. Data in A-E shown as median (min–max). Data 
missing for sCD14 in 1 patient with PSC. NS, not significant. 
Fig. 2. Levels of gut leakage markers and inflammatory bowel disease (IBD). (A) Increased 
soluble CD14 (sCD14) in both primary sclerosing cholangitis (PSC) patients with IBD 
(PSC+IBD, n = 121) and without IBD (PSC no IBD, n = 43) compared to both healthy 
controls (n = 100) and IBD patients without PSC (n = 40). IBD patients (all diagnosed with 
ulcerative colitis) also showed increased levels of sCD14 compared to healthy controls. (B) 
Only PSC patients with IBD have increased lipopolysaccharide-binding protein (LBP) levels 
compared to healthy controls, while PSC patients show similar LBP levels as IBD patients 
without PSC, irrespective of IBD status. Data shown as median (min–max). Data missing for 
sCD14 in n = 1, and IBD status for n = 2, all in the PSC group. NS, not significant. 
Fig. 3. Identification of optimal cut-offs for soluble CD14 (sCD14) and lipopolysaccharide-
binding protein (LBP) and corresponding Kaplan Meier survival analyses. Receiver operating 
characteristic (ROC) curve tests defined the optimal cut-off in the complete PSC population 
to differentiate patients with and without end point to be (A) 1638 ng/ml for sCD14, 
associated with a sensitivity of 74% and specificity of 70%, and (B) 13942 ng/ml for LBP, 
associated with a sensitivity of 55% and specificity of 64%. These cut-offs were then used to 
analyze liver transplantation free-survival in PSC patients stratified by (C) high and low 
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sCD14 (divided by cut-off from the ROC curve test above) and (D) by high and low LBP 
(divided by cut-off from the ROC curve test above). Data missing for sCD14 in n = 1. 
Fig. 4. Increased soluble CD14 (sCD14) levels in primary sclerosing cholangitis (PSC) 
patients with hepatobiliary cancer during follow-up. (A) sCD14 levels in healthy controls, 
PSC without cancer, PSC patients with cholangiocarcinoma (CC) and PSC patients with 
gallbladder cancer (GBC). (B) Kaplan Meier survival analysis of PSC patients without 
hepatobiliary cancer during follow-up (n = 140 (84.3%)), stratified by high and low sCD14 
(divided by median). Data in A shown as median (min–max). Data regarding hepatobiliary 
cancer during follow-up missing for n = 1, and sCD14 levels missing for n = 1 in the 
PSC+CC group. 
Fig. 5. High levels of soluble CD14 (sCD14) is associated with poor prognosis regardless of 
liver synthesis function while zonulin concentration is confounded. (A) Zonulin levels in 
healthy controls vs primary sclerosing cholangitis (PSC) patients stratified by high (≥1.2) and 
low (<1.2) international normalized ratio (INR). High sCD14 levels is associated with 
reduced liver transplantation-free survival in both PSC with (B) normal liver synthesis 
function (n = 115, defined by normal prothrombin time (INR £1.2) or (C) reduced liver 
synthesis function (n = 19, defined by increased prothrombin time (INR >1.2)). When 
stratifying patients according to Child-Pugh class, (D) high sCD14 levels is associated with 
reduced liver transplantation-free survival in patients in class A, while this is not the case in 
(E) patients in Child-Pugh Class B&C (classes were combined to achieve adequate sample 
size). Data for INR, sCD14 and Child-Pugh score missing for n = 32, n = 1 and n = 36, 
respectively. NS, not significant. 
Fig. 6. High levels of soluble CD14 (sCD14) is associated with poor prognosis regardless of 
C-reactive protein (CRP) levels and correlates with liver biochemistry. (A) After excluding 
primary sclerosing cholangitis (PSC) patients with high CRP (n = 40, defined as CRP >10), 
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high sCD14 was still associated with decreased liver transplantation-free survival (n = 112). 
Correlations between (B) cholestasis markers alkaline phosphatase (ALP) and sCD14 and (C) 
bilirubin and sCD14, and (D) lipopolysaccharide-binding protein (LBP) and bilirubin. Data 
on sCD14 and CRP missing for n = 1 and n = 14 PSC patients, respectively.  
 
